Frank Torti

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
London
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
By: /s/ Richard Pulik, as Attorney-in-Fact for Frank Torti
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Frank Torti

Form 4 holding President and Vant Chair

Roivant Sciences Ltd.

Security class
Stock Option (Right to Buy)
Shares / value
3,026,184
Estimated value
Report date
23 Feb 2026
Price
Ownership
Direct
Underlying class
Common Shares
Underlying amount
Form 4 holding Director

Immunovant, Inc.

Security class
Stock Option (right to buy)
Shares / value
88,325
Estimated value
Report date
07 Apr 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Arbutus Biopharma Corp

Security class
Stock Option (Right to Buy)
Shares / value
67,000
Estimated value
Report date
23 May 2024
Price
Ownership
Direct
Underlying class
Common Shares
Underlying amount

Insider Reports Filed by Frank Torti

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .